Please provide your email address to receive an email when new articles are posted on . Machine learning algorithms developed to predict improvement in patients with mild nonproliferative diabetic ...

Please provide your email address to receive an email when new articles are posted on . Four-year outcomes of the DRCR Retina Network Protocol W study showed that preventive aflibercept vs. sham ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Prophylactic ...

Central macular thickness and foveal avascular zone enlargement may serve as biomarkers for early diabetic retinopathy progression.

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

The preparation of evidence-based guidelines is highlighted by the WHO as an important component in the concerted effort to eliminate avoidable blindness. [149] This review has highlighted ...

CHICAGO -- Diabetic patients without retinopathy achieved 20/20 vision after cataract surgery as often as nondiabetic patients did, a retrospective analysis of a large community-based cohort showed.

To investigate the relationship between subfoveal choroidal thickness, severity of diabetic retinopathy (DR), and the presence of diabetic macular oedema (DMO) using enhanced depth imaging spectral ...

To report estimates of the prevalence of diabetic retinopathy (DR) and maculopathy grades for a large cohort of patients managed by the UK hospital eye service (HES). Between 2007 and 2010, 307 538 ...

BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...

COPENHAGEN, Denmark, June 24, 2025 /PRNewswire/ -- Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment ...

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients ...